This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

AboutSuspicionSuspicionRed flagsSuspicion toolsDiagnosisDiagnosisDiagnostic testingDiagnostic flow chartResourcesResourcesMaterialsVideos
Transthyretin cardiac amyloidosis*: an underdiagnosed, progressive, and infiltrative disease often overlooked as a cause of heart failure1-3
ATTR cardiac amyloidosis (ATTR-CM): an underdiagnosed, progressive, and infiltrative disease often overlooked as a cause of heart failure1-3
*Also known as transthyretin amyloid cardiomyopathy (ATTR-CM).Early, accurate diagnosis of ATTR cardiac amyloidosis can benefit patient care and may lead to improved outcomes.3,4 Learn more about what to look for to raise suspicion of ATTR cardiac amyloidosis and how to diagnose the disease.Early, accurate diagnosis of ATTR-CM may benefit patient care and lead to improved outcomes.3,4 Learn more about what to look for to raise suspicion of ATTR-CM and how to diagnose the disease.Disease overview & subtypesLearn moreLoadingRecognizing the clinical signsLearn moreLoadingDiagnosis of ATTR cardiac amyloidosisLearn moreLoadingATTR=transthyretin amyloidosis.
References:Law S, Gillmore JD. When to suspect and how to approach a diagnosis of amyloidosis. Am J Med. 2022;135(suppl 1):S2-S8. Kittleson M, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient with Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;S0735-1097(22)07423-X. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709-716. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-R1D-USA-1354
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
 
PP-MCL-USA-0367